Real-time Estimate
Cboe BZX
11:16:50 2024-04-29 am EDT
|
5-day change
|
1st Jan Change
|
34.48
USD
|
+1.23%
|
|
+0.88%
|
-9.47%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,243
|
1,657
|
1,073
|
1,797
|
1,614
|
-
|
-
|
Enterprise Value (EV)
1 |
1,144
|
1,597
|
1,001
|
1,797
|
1,614
|
1,614
|
1,614
|
P/E ratio
|
-11
x
|
-20.3
x
|
-6.81
x
|
-7.42
x
|
-8.64
x
|
-8.5
x
|
-11.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
96.5
x
|
229
x
|
490
x
|
998
x
|
-
|
809
x
|
13.2
x
|
EV / Revenue
|
96.5
x
|
229
x
|
490
x
|
998
x
|
-
|
809
x
|
13.2
x
|
EV / EBITDA
|
-18,718,797
x
|
-21,991,725
x
|
-8,390,728
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-25,204,277
x
|
-20,415,760
x
|
-9,251,959
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
11
x
|
32.5
x
|
18.5
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
37,712
|
37,955
|
43,551
|
47,291
|
47,392
|
-
|
-
|
Reference price
2 |
32.97
|
43.67
|
24.64
|
38.00
|
34.06
|
34.06
|
34.06
|
Announcement Date
|
3/12/21
|
2/28/22
|
3/6/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
12.89
|
7.231
|
2.192
|
1.8
|
-
|
1.995
|
122
|
EBITDA
|
-66.42
|
-75.37
|
-127.9
|
-
|
-
|
-
|
-
|
EBIT
1 |
-67.44
|
-76.56
|
-129.1
|
-219.2
|
-199.2
|
-251.7
|
-180.7
|
Operating Margin
|
-523.3%
|
-1,058.83%
|
-5,890.37%
|
-12,178.94%
|
-
|
-12,616.14%
|
-148.16%
|
Earnings before Tax (EBT)
1 |
-75.63
|
-81.77
|
-145.2
|
-239.7
|
-199.2
|
-251.7
|
-180.7
|
Net income
1 |
-76.12
|
-81.77
|
-145.2
|
-241.4
|
-199.2
|
-251.7
|
-180.7
|
Net margin
|
-590.66%
|
-1,130.8%
|
-6,625.27%
|
-13,408.94%
|
-
|
-12,616.14%
|
-148.16%
|
EPS
2 |
-3.010
|
-2.150
|
-3.620
|
-5.120
|
-3.943
|
-4.005
|
-3.070
|
Free Cash Flow
|
-49.33
|
-81.19
|
-116
|
-
|
-
|
-
|
-
|
FCF margin
|
-382.77%
|
-1,122.76%
|
-5,291.38%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/21
|
2/28/22
|
3/6/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
2.532
|
2.856
|
0.929
|
0.711
|
0.278
|
0.274
|
0.017
|
0.03
|
0.119
|
1.634
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-18.8
|
-19.4
|
-29.02
|
-34.6
|
-30
|
-35.5
|
-43.77
|
-41.34
|
-45.83
|
-88.29
|
-47.87
|
-48.15
|
-50.51
|
-52.68
|
Operating Margin
|
-742.54%
|
-679.41%
|
-3,123.47%
|
-4,865.96%
|
-10,792.45%
|
-12,956.2%
|
-257,447.06%
|
-137,796.67%
|
-38,510.08%
|
-5,403.24%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-20.58
|
-21.19
|
-31.25
|
-37.73
|
-35.32
|
-40.92
|
-48.92
|
-47.05
|
-51.79
|
-91.97
|
-47.87
|
-48.15
|
-50.51
|
-52.68
|
Net income
1 |
-20.58
|
-21.19
|
-31.25
|
-37.73
|
-35.32
|
-40.92
|
-48.92
|
-47.05
|
-51.79
|
-93.6
|
-47.87
|
-48.15
|
-50.51
|
-52.68
|
Net margin
|
-812.8%
|
-741.91%
|
-3,364.26%
|
-5,306.89%
|
-12,706.83%
|
-14,932.48%
|
-287,741.18%
|
-156,840%
|
-43,520.17%
|
-5,728.52%
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5400
|
-0.5500
|
-0.8000
|
-0.9700
|
-0.9000
|
-0.9500
|
-1.120
|
-1.080
|
-1.100
|
-1.730
|
-1.010
|
-1.020
|
-0.9600
|
-0.9200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
2/28/22
|
5/9/22
|
8/8/22
|
11/7/22
|
3/6/23
|
5/8/23
|
8/7/23
|
11/9/23
|
2/28/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
99.4
|
60.8
|
71.8
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-49.3
|
-81.2
|
-116
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-128%
|
-263%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
2.990
|
1.340
|
1.330
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-1.900
|
-2.110
|
-2.870
|
-
|
-
|
-
|
-
|
Capex
|
1.36
|
0.86
|
0.69
|
-
|
-
|
-
|
-
|
Capex / Sales
|
10.58%
|
11.95%
|
31.3%
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/21
|
2/28/22
|
3/6/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
34.06
USD Average target price
35.5
USD Spread / Average Target +4.23% Consensus |
1st Jan change
|
Capi.
|
---|
| -9.47% | 1.61B | | -2.70% | 103B | | +1.67% | 95.28B | | +1.72% | 22.15B | | -15.45% | 21.02B | | -8.58% | 18.15B | | -41.01% | 16.73B | | -13.38% | 16.05B | | +4.03% | 13.68B | | +34.74% | 12.17B |
Bio Therapeutic Drugs
|